Ignite Creation Date:
2024-06-16 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06447623
Status:
RECRUITING
Last Update Posted:
2024-06-07
First Post:
2024-06-03
Brief Title:
Apatinib Combined With cdk46i in First-line Treatment for HRHER2- SNF4 Subtype Breast Cancer
Sponsor:
Fudan University
Organization:
Fudan University
Study Overview
Official Title:
Study of Efficacy of Apatinib Combined With cdk46i in First-line Treatment for HRHER2- SNF4 Subtype Advanced Breast Cancer Open Randomized Phase III
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a randomized controlled open-label phase III study to explore the efficacy and safety of Apatinib in combination with standard first-line endocrine therapy for the HR HER2-SNF4 subtype of advanced breast cancer The study was used to explore the efficacy of Apatinib in combination with standard endocrine therapy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None